NASDAQ:THAR Tharimmune (THAR) Stock Price, News & Analysis $3.13 +0.08 (+2.62%) Closing price 09/11/2025 04:00 PM EasternExtended Trading$3.34 +0.21 (+6.55%) As of 09:16 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Tharimmune Stock (NASDAQ:THAR) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Tharimmune alerts:Sign Up Key Stats Today's Range$2.92▼$3.2050-Day Range$1.17▼$7.7152-Week Range$0.95▼$9.08Volume794,966 shsAverage Volume31.22 million shsMarket Capitalization$17.81 millionP/E RatioN/ADividend YieldN/APrice Target$17.00Consensus RatingStrong Buy Company Overview Tharimmune, Inc., a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1). It has a research collaboration and product license agreement with Minotaur Therapeutics, Inc. for the development of proprietary targeted biologics; and Washington University in St. Louis for the rights to develop and commercialize technology related to multiple hybridomas and antibodies directed specifically towards human HER2. The company was formerly known as Hillstream BioPharma, Inc. and changed its name to Tharimmune, Inc. in September 2023. Tharimmune, Inc. was incorporated in 2017 and is headquartered in Bridgewater, New Jersey. Read More Tharimmune Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks50th Percentile Overall ScoreTHAR MarketRank™: Tharimmune scored higher than 50% of companies evaluated by MarketBeat, and ranked 589th out of 947 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.8 / 5Analyst RatingStrong Buy Consensus RatingTharimmune has received a consensus rating of Strong Buy. The company's average rating score is 3.50, and is based on 1 buy rating, no hold ratings, and no sell ratings.Upside PotentialTharimmune has a consensus price target of $17.00, representing about 443.1% upside from its current price of $3.13.Amount of Analyst CoverageTharimmune has received no research coverage in the past 90 days.Read more about Tharimmune's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Tharimmune is -0.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Tharimmune is -0.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTharimmune has a P/B Ratio of 4.60. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted35.42% of the float of Tharimmune has been sold short.Short Interest Ratio / Days to CoverTharimmune has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Tharimmune has recently increased by 943.04%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldTharimmune does not currently pay a dividend.Dividend GrowthTharimmune does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted35.42% of the float of Tharimmune has been sold short.Short Interest Ratio / Days to CoverTharimmune has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Tharimmune has recently increased by 943.04%, indicating that investor sentiment is decreasing significantly. News and Social Media3.1 / 5News Sentiment0.58 News SentimentTharimmune has a news sentiment score of 0.58. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.01 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Tharimmune this week, compared to 1 article on an average week.Search Interest35 people have searched for THAR on MarketBeat in the last 30 days. This is an increase of 1,067% compared to the previous 30 days.MarketBeat Follows11 people have added Tharimmune to their MarketBeat watchlist in the last 30 days. This is an increase of 267% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, Tharimmune insiders have bought more of their company's stock than they have sold. Specifically, they have bought $592,464.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders10.01% of the stock of Tharimmune is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 1.16% of the stock of Tharimmune is held by institutions.Read more about Tharimmune's insider trading history. Receive THAR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Tharimmune and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. THAR Stock News HeadlinesShort Interest in Tharimmune, Inc. (NASDAQ:THAR) Grows By 943.0%September 12 at 4:13 AM | americanbankingnews.comAnalyzing Roivant Sciences (NASDAQ:ROIV) & Tharimmune (NASDAQ:THAR)September 11 at 3:15 AM | americanbankingnews.comNew law could create $3.7 trillion tsunami.During a meeting in Washington D.C., Jeff Brown discovered a bold initiative. He calls it “President Trump’s Project MAFA,” and it could soon return America to a “new” gold standard. The Trump administration, Wall Street, and Silicon Valley are all pushing it forward. The President himself calls the plan “incredible.” Already, it’s helping small plays jump as high as 300%, 318%, 520%, and even 600%.September 12 at 2:00 AM | Brownstone Research (Ad)Tharimmune Achieves Nasdaq Compliance, Stabilizing Market PositionSeptember 5, 2025 | tipranks.comTharimmune Secures Nasdaq Listing with $7.05M RaiseSeptember 5, 2025 | tipranks.comTharimmune, Inc. to Present Innovative Research at Upcoming Fall Conferences in 2025September 4, 2025 | quiverquant.comQTharimmune (THUR) Tumbles 20.7% on $5-Million Share SaleAugust 27, 2025 | insidermonkey.comTharimmune files to sell 2.46M shares of common stock for holdersAugust 26, 2025 | msn.comSee More Headlines THAR Stock Analysis - Frequently Asked Questions How have THAR shares performed this year? Tharimmune's stock was trading at $2.03 on January 1st, 2025. Since then, THAR shares have increased by 54.2% and is now trading at $3.13. How were Tharimmune's earnings last quarter? Tharimmune, Inc. (NASDAQ:THAR) announced its quarterly earnings data on Thursday, August, 14th. The company reported ($0.64) earnings per share for the quarter, missing analysts' consensus estimates of ($0.58) by $0.06. When did Tharimmune's stock split? Shares of Tharimmune reverse split on Tuesday, May 28th 2024.The 1-15 reverse split was announced on Tuesday, May 28th 2024. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, May 28th 2024. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. Who are Tharimmune's major shareholders? Top institutional shareholders of Tharimmune include Franklin Resources Inc. (1.07%) and XTX Topco Ltd (0.31%). Insiders that own company stock include Gravitas Capital Lp, Sireesh Appajosyula, Randy Milby and Sanam Parikh. View institutional ownership trends. How do I buy shares of Tharimmune? Shares of THAR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Tharimmune own? Based on aggregate information from My MarketBeat watchlists, some other companies that Tharimmune investors own include Jiuzi (JZXN), Avenue Therapeutics (ATXI), Scinai Immunotherapeutics (SCNI), Adial Pharmaceuticals (ADIL), Sphere 3D (ANY), Blackboxstocks (BLBX). Company Calendar Last Earnings8/14/2025Today9/11/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:THAR Previous SymbolNASDAQ:THAR CIK1861657 Webwww.hillstreambio.com Phone908-955-3140FaxN/AEmployees2Year FoundedN/APrice Target and Rating Average Price Target for Tharimmune$17.00 High Price Target$17.00 Low Price Target$17.00 Potential Upside/Downside+443.1%Consensus RatingStrong Buy Rating Score (0-4)3.50 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)($6.10) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$12.20 million Net MarginsN/A Pretax MarginN/A Return on Equity-1,239.20% Return on Assets-365.06% Debt Debt-to-Equity RatioN/A Current Ratio1.17 Quick Ratio1.17 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.68 per share Price / Book4.60Miscellaneous Outstanding Shares5,690,000Free Float5,121,000Market Cap$17.81 million OptionableNot Optionable Beta1.56 These 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:THAR) was last updated on 9/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredCollege grad makes $64,000 a monthIt's easy to feel like you've missed out on the biggest stock market boom of the century. But if you want t...Stansberry Research | SponsoredUrgent: $3,452.50 a Month in Passive "AI Equity Checks"The U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | Sponsored2013 Bitcoin miner reveals his trading system (free)There are 18,347 cryptocurrencies in the market right now. 99% of them will fail. And trying to pick winner...Crypto Swap Profits | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tharimmune, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tharimmune With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.